A. B. Gottlieb, “BMS-986165, an Oral, Selective TYK2 Inhibitor, in the Treatment of Moderate to Severe Psoriasis as Assessed by the Static Physician’s Global Assessment (sPGA)/Body Surface Area (BSA) Composite Tool (sPGAxBSA), a Clinically Useful Alternative to PASI”, J of Skin, vol. 4, no. 5, p. s29, Sep. 2020.